Trading in NeurogesX Common Stock to Move From NASDAQ to OTCBB
June 29, 2012 06:00 ET
|
NeurogesX
SAN MATEO, Calif., June 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Receives Notice of Two U.S. Patent Allowances Covering NGX-1998
June 19, 2012 08:00 ET
|
NeurogesX
SAN MATEO, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Issued Japanese Patent for NGX-1998
June 18, 2012 08:00 ET
|
NeurogesX
SAN MATEO, Calif., June 18, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Reports First Quarter 2012 Results
May 03, 2012 16:05 ET
|
NeurogesX
Q1 2012 and Recent Highlights:
Engaged JSB-Partners, a global life sciences advisor, to assist the Company in executing its business development objectives for NGX-1998 and...
NeurogesX to Hold Conference Call to Discuss First Quarter 2012 Results
April 27, 2012 09:00 ET
|
NeurogesX
SAN MATEO, Calif., April 27, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Receives Determination Letter From NASDAQ
April 20, 2012 16:05 ET
|
NeurogesX
SAN MATEO, Calif., April 20, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Engages JSB-Partners to Execute Business Development Strategy
April 17, 2012 07:30 ET
|
NeurogesX
SAN MATEO, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Provides Update on NGX-1998 Clinical Program
April 11, 2012 07:30 ET
|
NeurogesX
SAN MATEO, Calif., April 11, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...
NeurogesX Reports Fourth Quarter and Year-End 2011 Results
March 08, 2012 07:30 ET
|
NeurogesX
Q4 2011 and Recent Highlights:
Positive NGX-1998 Phase 2 clinical trial in postherpetic neuralgia (PHN) patients met all study objectives
Qutenza Q4 revenue totaled $3.0 million, including...
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Full Year 2011 Results
February 29, 2012 08:30 ET
|
NeurogesX
SAN MATEO, Calif., Feb. 29, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain...